(NASDAQ: KYNB) Kyntra Bio's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 15.39%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 76.07%.
Kyntra Bio's earnings in 2026 is $183,452,000.On average, 4 Wall Street analysts forecast KYNB's earnings for 2026 to be -$49,326,774, with the lowest KYNB earnings forecast at -$68,966,835, and the highest KYNB earnings forecast at -$27,662,086. On average, 4 Wall Street analysts forecast KYNB's earnings for 2027 to be -$43,981,321, with the lowest KYNB earnings forecast at -$58,100,295, and the highest KYNB earnings forecast at -$28,299,461.
In 2028, KYNB is forecast to generate -$28,522,846 in earnings, with the lowest earnings forecast at -$27,404,303 and the highest earnings forecast at -$29,361,753.